Stay updated on LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The LAVA-051 clinical trial has been terminated due to a strategic business decision, not safety concerns, and the trial's scope has shifted from a Phase 1/2a to a Phase 1 trial focused on patients with relapsed or refractory CLL, MM, or AML.
    Difference
    11%
    Check dated 2025-02-03T08:44:48.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Difference
    1%
    Check dated 2025-01-27T03:38:55.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    1%
    Check dated 2025-01-19T22:52:35.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    2%
    Check dated 2025-01-12T18:25:07.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2025-01-05T14:25:02.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-12-29T07:52:00.000Z thumbnail image

Stay in the know with updates to LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.